Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
I124-NM404 · 1 trial · 1 indication
The objective of this protocol is to obtain preliminary data on imaging NSCLC tumors. Images with 124I-NM404 will be evaluated by a nuclear medicine consultant, who will be blind to the participants' clinical findings and other radiographic images. The nuclear medicine consultant will independently record his findings, and then compare his results with those obtained by conventional FDG-PET imaging that was done at baseline as part of this study. This comparison will be only qualitative.
| Arm | Type | Description |
|---|---|---|
| Diagnostic: iodine I-124 NM404 CT/PET scan | OTHER | Patients undergo iodine I-124 NM404 CT/PET scan at 1-2, 4-6, 24, and 48 hours and at 5-10 days. |
| Name | Type | Description |
|---|---|---|
| I124-NM404 | DRUG | I-124-NM404 |
Inclusion Criteria: Part 3 * Histologically or cytologically documented NSCLC with measurable of disease * Disease is evaluable by CT scan * At least 18 years old. Women cannot be pregnant or breastfeeding * Karnofsky score \>/= to 60 * Adequate renal/hepatic function * Adequate blood cell count le...
Top 20 of 90 competitors
I124-NM404 is an investigational small molecule being studied for use in Non Small Cell Lung Cancer (NSCLC). It was evaluated in a Phase 1 clinical trial as an imaging agent in patients with NSCLC. The drug is being developed by Cellectar Biosciences, Inc. (CLRB) and is currently in clinical development.
The molecular target of I124-NM404 has not been disclosed. It is a small molecule being studied as an imaging agent in Non Small Cell Lung Cancer. The drug is in Phase 1 clinical development by Cellectar Biosciences, Inc. (CLRB).
I124-NM404 is being developed by Cellectar Biosciences, Inc., a biopharmaceutical company traded on the Nasdaq under the ticker symbol CLRB. The company is conducting clinical research on this investigational small molecule for Non Small Cell Lung Cancer.
I124-NM404 is in Phase 1 clinical development. It has completed one Phase 1 trial in Non Small Cell Lung Cancer. The drug is investigational and has not been approved by the FDA. Cellectar Biosciences, Inc. (CLRB) is the developer.
I124-NM404 has been studied in one completed Phase 1 clinical trial, identified as NCT00582283. This trial evaluated NM404 as an imaging agent in patients with Non Small Cell Lung Cancer in the United States. The study enrolled 21 participants and was not randomized or blinded.
Yes, I124-NM404 is also known as NM404. The completed Phase 1 clinical trial NCT00582283 used the name NM404 in its title. Both names refer to the same investigational small molecule being developed by Cellectar Biosciences, Inc. (CLRB) for Non Small Cell Lung Cancer.